Dec 19, 2023

Zai Lab Announces Participation in January Investor Conference

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 19, 2023-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024:

J.P. Morgan 42nd Annual Healthcare Conference
Presentation: Monday, January 8, 2024, 3:45 p.m. PST
Location: San Francisco

A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website at and archived replay will be available for up to 90 days following the completion of the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit or follow us at

Investor Relations:
Christine Chiou / Lina Zhang
+1 (917) 886-6929 / +86 136 8257 6943 /

Shaun Maccoun / Xiaoyu Chen
+1 (415) 317-7255 / +86 185 0015 5011 /

Source: Zai Lab Limited